Mirae Asset Global Investments
RAPP

Mirae Asset Global Investments’s Rapport Therapeutics RAPP Stock Holding History

Mirae Asset Global Investments’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89.1K Sell
2,139
-347
-14% -$12.8K ﹤0.01% 1258
2026
Q1 		$77.8K Buy
2,486
+170
+7% +$4.78K ﹤0.01% 1220
2025
Q4 		$70.3K Buy
2,316
+905
+64% +$25K ﹤0.01% 1332
2025
Q3 		$41.9K Buy
1,411
+1
+0.1% +$18 ﹤0.01% 1378
2025
Q2 		$16K Buy
1,410
+144
+11% +$1.53K ﹤0.01% 1424
2025
Q1 		$12.7K Buy
1,266
+47
+4% +$610 ﹤0.01% 1447
2024
Q4 		$23.2K Buy
+1,219
New +$27K ﹤0.01% 1401

Other funds holding RAPP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Mirae Asset Global Investments's RAPP Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Rapport Therapeutics (RAPP) stake by 14% in Q2 2026, selling an estimated $12.8K and leaving 2,139 shares worth $89.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1258.

Mirae Asset Global Investments first reported a position in RAPP in Q4 2024 and has held it in 7 quarters since. 47 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Mirae Asset Global Investments held 2,139 shares of Rapport Therapeutics worth $89.1K as of Q2 2026.
  • Mirae Asset Global Investments sold 347 Rapport Therapeutics shares in Q2 2026, an estimated $12.8K.
  • Rapport Therapeutics made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1258 holding.
  • Mirae Asset Global Investments first reported a position in Rapport Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 47 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.